GAVI facts and figures

in page functions
[French]

Statistics measuring Gavi, the Vaccine Alliance's impact on global immunisation

Every year, academics, journalists, teachers and students ask for statistics detailing Gavi's results since the Vaccine Alliance was established in 2000. Sourcing the Gavi Secretariat and members of the Vaccine Alliance, including WHO, UNICEF and civil society organisations, these key facts and figures list Gavi's achievements to date as well as demonstrating the Vaccine Alliance's catalytic role within global immunisation.

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

>65 million

In 2015 alone, more than 65 million children were immunised with Gavi-supported vaccines. This equates to more than over 195 million points of contact between these children and the primary health system and can provide a robust platform for other health interventions.

Source: WHO/UNICEF 2015

>200

Gavi supported more than 200 vaccine introductions and campaigns in the 2011–2015 period – four times as many as in the previous five years.

Source: Gavi

>60

The Vaccine Alliance has helped to strengthen health systems and immunisation services and increase injection safety in more than 60 countries.

Source: Gavi

1 million

Since the first human papillomavirus (HPV) vaccine demonstration programme in Kenya in 2013, 1 million girls have been immunised with Gavi support. Gavi is already funding national HPV vaccine programmes in Rwanda and Uganda.

Source: Gavi

10 million

In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of 2015, 38 countries had introduced the vaccine with our support, collectively immunising 10 million children.

Source: Gavi

32 million

Since 2007, countries have immunised 32 million children with a second dose of measles vaccine with Gavi support. Gavi- funded measles campaigns have helped vaccinate another 118 million children in countries at high risk of outbreaks.

Source: WHO/UNICEF 2016

164 million

By the end of 2015, Gavi-funded measles-rubella catch-up campaigns, targeting the next generation of mothers and children aged 9 months to 14 years, had reached 164 million people.

Source: WHO/UNICEF 2016

>98 million

Since 2011, Gavi-supported campaigns have protected over 98 million people in 14 countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation, immunising more than 90 million children.

Source: Gavi

>1 million

Since its creation in 2013, the global oral cholera vaccine stockpile has been used to vaccinate more than 1 million people; in 2015, campaigns took place in Bangladesh, Cameroon, Haiti, Malawi, Tanzania and South Sudan.

Source: Gavi

US$ 1 = US$ 18

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Source: Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

235 million

By the end of 2015, 16 countries in the African meningitis belt had collectively immunised 235 million people against meningitis A with support from Gavi.

Source: WHO 2014

95%

Over 95% of children in Gavi-supported countries do not yet have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF 2015

Every 2 minutes

One woman dies from cervical cancer every two minutes - or 266,000 a year - over 85% in the developing world. Two-thirds of all cervical cancer deaths can be prevented with HPV vaccines.

Source: WHO

>8 million

Since its inception in 2000, Gavi has helped developing countries to prevent more than 8 million future deaths through its support to 10 vaccines: pentavalent, pneumococcal, rotavirus, yellow fever, meningitis A, Japanese encephalitis, human papillomavirus, measles second dose, measles-rubella and rubella.

Source: Gavi / Bill & Melinda Gates Foundation 2016

Close to 580 million

Since 2000, Gavi support has contributed to the immunisation of close to 580 million children.

Source: WHO/UNICEF 2016

76 million

By the end of 2015, Gavi had contributed to immunising 76 million children against pneumococcal disease. Gavi surpassed its 2015 target of 45 introductions already in 2014 – more than one year ahead of schedule. By the end of 2015, three-quarters of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2016

277 million

Gavi support helped countries to immunise 277 million children between 2011 and 2015.

Source: WHO/UNICEF 2016

26%

Pneumonia and diarrhoea account for 26% of deaths in under-fives in Gavi-supported countries.

Source: CHERG-WHO 2014

20 by 2020

Gavi continues to help countries to build sustainable immunisation programmes. Four countries started to fully self- finance their vaccines in early 2016; close to 20 others are preparing to transition out of Gavi support by 2020.

Source: Gavi

>36 million

Vaccine Alliance support has contributed to immunising more than 36 million children against rotavirus diarrhoea. By the end of 2015, more than half of all Gavi-supported countries had introduced the vaccine.

Source: WHO/UNICEF 2016

>4 million

The Vaccine Alliance’s support for vaccines contributed to averting more than 4 million future deaths between 2011 and 2015.

Source: Gavi, the Vaccine Alliance/Bill & Melinda Gates Foundation 2016

44%

The weighted average price of pentavalent vaccine per dose dropped from US$ 2.98 in 2010 to US$ 1.68 in 2015: a reduction of 44%.

Source: Gavi

1.5 million

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

5 -> 16

From 5 to 16 vaccine manufacturers supplying Gavi – over half based in emerging markets.

2001: 5 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 1 based in an emerging market;
2015: 16 vaccine manufacturers producing prequalified, appropriate Gavi vaccines – 9 based in emerging markets.

Source: Gavi 2016

19 million

19 million infants remain under-immunised with three doses of DTP in the world each year. Almost one in five of all children in Gavi-supported countries miss out on a full course of this basic package of vaccines.

Source: WHO/UNICEF 2016

close icon

modal window here